Subthreshold Depression in Parkinson's Disease

Department of Psychiatry, Zentrum für Integrative Psychiatrie, Kiel, Germany.
Movement Disorders (Impact Factor: 5.68). 08/2011; 26(9):1741-4. DOI: 10.1002/mds.23699
Source: PubMed

ABSTRACT Quality of life in Parkinson patients with subthreshold depression could be improved if the prevalence and symptom profile were better understood.
Our study used standard DSM-IV and Judd criteria as well as motor, depression, and quality-of-life scales to investigate a sample of 110 nondemented Parkinson patients. This led to formation of nondepressed (48.2%), subthreshold depressed (25.5%), and depressed (26.4%) groups.
Quality of life was seen to be significantly lower in subthreshold depressed patients than in the nondepressed, and there were differences in the frequency of depressive symptoms that partially overlapped with nonmotor symptoms of vegetative origin in Parkinson's disease (appetite, sleep disorders). Key measures of depression (diminished interest/pleasure) were more frequent in the depressed group compared with the subthreshold depressed, although the motor functions of these 2 groups did not differ significantly.
The Beck Depression Inventory score ranging from 9 to 15 points differentiates subthreshold depressed from nondepressed and depressed patients best.

20 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: The study was aimed to examine the prevalence of depression in patients with Parkinson's disease (PD) and identify its features. A total of 131 out-patients, diagnosed as having idiopathic PD in accordance with the United Kingdom Parkinson's Disease Society Brain Bank criteria, were interviewed with questionnaire and evaluated by Mini-Mental State Examination (MMSE), Unified Parkinson's Disease Rating Scale (UPDRS), Hohen &Yahr staging (H&Y staging) and Hamilton Rating Scale for Depression (HRSD). Patients were divided into three groups in terms of HRSD score: depression group, sub-threshold depression group and non-depression group. The clinical variables and symptom profiles were obtained and compared among the three groups. The results showed that 27 patients (20.6%) fell into the depression group, 71 (54.2%) into the sub-threshold depression group, and 33 (25.2%) into the non-depression group. There were no differences in age, gender or tremor score among the groups (P>0.05). Significant differences were found in duration of PD, UPDRS score, rigidity score and H&Y stage between the sub-threshold depression group (or the depression group) and the non-depression group (P<0.05). Moreover, the clinical variables in the subthreshold depression group had the trend of increasing with the severity of PD and their values were similar to those in the depression group. Anhedonia, feeling of incapability, sleep disturbance, gastrointestinal symptoms and depressive moods were most common in the depression group. And these symptoms also were more common in the other two groups. It is concluded that depression and sub-threshold depression are common in PD and share similar clinical features. Furthermore, subthreshold depression might be the prodrome of depression and may develop into depression as the condition progresses.
    Journal of Huazhong University of Science and Technology 12/2009; 29(6):725-8. DOI:10.1007/s11596-009-0610-6 · 0.83 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Neurostimulation of the subthalamic nucleus is an established treatment for advanced Parkinson's disease, and it might be the second milestone in treatment of Parkinson's disease after the introduction of L-dopa and dopamine agonists. However there are cognitive and psychiatric adverse effects have attracted increasing attention. In this context the subthalamic nucleus (STN) and the stimulation of the STN has been highlighted. The STN is part of the basal ganglia that are considered as part of distributed cortico-subcortical networks, which are involved in the selection, facilitation and inhibition of movements, emotions, behaviors and thoughts. Within this conception of the basal ganglia as a global "Go-/No-go-system" the STN is viewed as a central regulator. Those behavioral or cognitive effects of STN high frequency stimulation which can be modulated by changes in stimulation are therefore likely reflecting the intrinsic role of the STN in non-motor domains. However, there is insufficient knowledge about which proportion of Neuropsychiatric effects directly relates to such a modulation of the intrinsic basal ganglia state or which individual susceptibility factors may contribute to their clinical presentation. In this review the role of the preoperative factors and also the relevance of the intraoperative and postoperative management is analyzed.
    Parkinsonism & Related Disorders 01/2012; 18 Suppl 1:S168-70. DOI:10.1016/S1353-8020(11)70052-9 · 3.97 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Parkinson's disease (PD) has initially been described as a clinical syndrome, although its exact definition has changed over the past centuries. The identification of the pathological changes added another level of complexity, with Lewy bodies, synuclein deposits and neuronal loss in the substantia nigra being used alternatively as criteria. A third level of complexity was added with the recognition of genetic mutations resulting in Parkinsonism, sometimes with and sometimes without Lewy bodies or synuclein deposition. Lastly, frequent additional important pre-motor manifestations, particularly depression, anosmia and sleep-associated phenomena have been described. These different points of view on the definition of PD have important implications on the study of the etiology and even the therapy of PD. Cognitive impairment is also an important feature of PD, while the spectrum of deficits ranges from none to severe dementia. The no-man land in-between normal cognition and dementia has been termed mild cognitive impairment in PD. At present, this term lacks heuristic value or clinical utility, and remains a target for scientific research.
    Journal of Neural Transmission 03/2013; 120(4). DOI:10.1007/s00702-013-1006-0 · 2.40 Impact Factor
Show more